ICOS to Participate in Two Upcoming Healthcare Conferences
Monday October 27, 8:00 pm ET
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 27, 2003--ICOS Corporation (Nasdaq:ICOS - News) announced today that it will participate in the RBC Dain Rauscher Premiere Client Conference on November 11, 2003 and the Credit Suisse First Boston Health Care Conference on November 13, 2003.
RBC Dain Rauscher Premiere Client Conference Presentation
Date: November 11, 2003
Time: 2:30 p.m. EST
Speaker: Gary L. Wilcox, Ph.D., Executive Vice President,
Operations
A webcast of this ICOS presentation will be available in
real-time and a replay will be available through
November 18, 2003. The webcast can be accessed through the
ICOS website, www.icos.com, Investor - Events section
Credit Suisse First Boston Health Care Conference Presentation
Date: November 13, 2003
Time: 11:30 a.m. EST
Speaker: Paul N. Clark, Chairman, CEO and President
A webcast of this ICOS presentation will be available in
real-time and a replay will be available through
November 20, 2003. The webcast can be accessed through the
ICOS website, www.icos.com, Investor - Events section
Additional information on ICOS, including past press releases, is available at www.icos.com.
ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, and sepsis and other inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing opportunities to market breakthrough products.
The forward-looking statements contained in this press release represent the Company's judgment as of the date of this release. ICOS undertakes no obligation to publicly update any forward-looking statements. The biotechnology and pharmaceutical businesses are risky and there can be no assurance that any particular product candidate will progress and become a commercial product.
Contact:
ICOS Corporation
Lacy Fitzpatrick, 425-415-2207
Source: ICOS Corporation |
